迪戈辛及其Na+/K+-ATPase针对心血管疾病和癌症的向作用
Yulin Ren1, Andrew T Anderson1, Gunnar Meyer1
1Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Na+/K+-ATPase (NKA) 对于细胞功能和疾病治疗至关重要. 作为NKA抑制剂的迪戈辛在心血管疾病和癌症方面表现有前途,其类似物提供了新的治疗途径.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- Na+/K+-ATPase (NKA) 调节离子梯度,影响细胞过程,并作为治疗点.
- 心脏糖化物,如狄戈辛,抑制NKA,并用于心力衰竭.
- 迪戈辛通过向HIF-1α,NKA和NF-κB显示出潜在的抗瘤活性.
研究的目的:
- 审查NKA在心血管疾病和癌症中的作用.
- 讨论狄戈辛在这些疾病上的治疗效果.
- 为了探索迪戈辛类似物抗瘤潜力.
主要方法:
- 关于NKA功能的文献综述.
- 在心血管疾病和癌症中分析狄戈辛的机制.
- 对心脏葡萄糖类类似物抗瘤性质的评估.
主要成果:
- NKA与心血管疾病和癌症进展有关.
- 迪戈辛在心血管疾病和癌症中都表现出治疗潜力.
- 几种迪戈辛类似物显示出作为抗瘤剂的前景.
结论:
- NKA是心血管疾病和癌症的重要治疗点.
- 迪戈辛及其类似物是开发新药的有前途的候选药物.
- 对心脏糖的进一步研究可能会为复杂疾病提供新的治疗方法.
更多相关视频
09:20Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
09:35Preclinical Cardiac Electrophysiology Assessment by Dual Voltage and Calcium Optical Mapping of Human Organotypic Cardiac Slices
Published on: June 16, 2020
相关概念视频
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
